Despite demonstrating promise in targeting RIPK1 for the treatment of Alzheimer’s disease, SAR443060, another orally bioavailable CNS penetrant investigational agent, was abandoned due to long-term toxicities (Vissers et al., 2022). The gene discussed is RIPK1; the disease is early-onset autosomal dominant Alzheimer disease.